Bruce has been an active American Chemical Society member who routinely presents his science at national, regional and local ACS meetings and has overall outstanding achievements in, and contributions to, science, the profession and the Society. Bruce has retired since he was elected as an ACS fellow, but his career was dedicated to identifying active compounds to help the quality of life of people with illnesses: successes such as the anti-epilepsy/anti-migraine drug TOPAMAX® topiramate have had a remarkable effect on those afflicted!
Key Professional Service.
Dr. Maryanoff has served in numerous capacities: the Editorial Advisory Boards of 13 journals, including J. Med. Chem., J. Org. Chem., and Org. Lett.; a 4-year term on the Medicinal Chemistry Study Section of the National Institutes of Health; a 4-year term on the Advisory Board of the ACS Petroleum Research Fund; Chairman of the 1989 Gordon Research Conference on Organic Reactions and Processes; member of the Board of Directors of the ACS Philadelphia Section (1984-1986); and Chair of the Philadelphia Organic Chemists’ Club (1980-1982). He has organized and chaired several symposia at ACS National and Regional meetings, organized/edited a special issue of J. Med. Chem. to honor the memory of Dr. Paul A.J. Janssen (published in 2005), organized/edited a special issue of J. Med. Chem. to commemorate the centennial of MEDI (that was published in 2009), and was the inaugural editor of the book series Advances in Medicinal Chemistry (1988-1998). He participated as a speaker in the ACS/Council on Scientific and Industrial Research, India, Joint Scientific Symposia (2006) (he was part of the ACS contingent which toured and lectured in India), and an ACS ProSpectives Series on “Advances in Structure-Based Drug Discovery” (2005).
Other ACS Activities.
Dr. Maryanoff has been a member of the ACS for over 40 years. He has participated in 45 ACS National, Regional and Global (e.g., Pacifichem) meetings and has contributed 93 scientific papers to these meetings. He served as Chairman, Philadelphia Section Membership Committee, 1986-1987; Member, Philadelphia Section Award Committee, 1986-1988; Member, ACS Canvassing Committee for the Claude S. Hudson Award, 1990-1993; Member, ACS Division of Medicinal Chemistry Award Committee, 2001; Member, Award Selection Committee for the 2005 Smissman Award from ACS Division of Medicinal Chemistry, 2004; Member, Award Selection Committee for the ACS Award in Industrial Chemistry, 2003-2005
Awards and Honors.
Dr. Maryanoff has received two ACS National awards, a 2000 ACS Heroes of Chemistry Award and the 2003 ACS Award in Industrial Chemistry. He was inducted into the ACS Medicinal Chemistry Division Hall of Fame in 2008. He received the 2009 Edward E. Smissman Award from the ACS Division of Medicinal Chemistry, the Philadelphia Section Award of the American Chemical Society, 1984, and a Philadelphia Organic Chemists' Club Award (1995). He was honored with a Johnson Medal for Research and Development for discovery and development of TOPAMAX®, and was twice a recipient Johnson & Johnson's Philip B. Hofmann Research Scientist Award. Dr. Maryanoff was recognized by Drexel University as a notable alumnus with several awards, including election to the Drexel Alumni 100 Club. He was elected a Fellow of the American Association for the Advancement of Science (1989) and a Fellow of the Royal Society of Chemistry (2000).
Dr. Bruce E. Maryanoff earned a BS in chemistry (1969) and a PhD in organic chemistry (1972) from Drexel University, working with Prof. Robert Hutchins. He conducted postdoctoral studies for two years at Princeton University, with Prof. Kurt Mislow, and had a major impact on the area of thiabenzenes. He joined McNeil Laboratories, a Johnson & Johnson subsidiary and advanced on the scientific ladder in various Johnson & Johnson pharmaceutical units to the highest scientific position in the company. In 2009 he was a Distinguished Research Fellow and a Team Leader in Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA. Dr. Maryanoff is an internationally renowned expert in drug design and drug discovery, and is among the few highly recognized and acclaimed industrial chemists in the USA.
Independent Scientific Contributions.
Dr. Maryanoff has made numerous contributions in medicinal and organic chemistry. From 1976-1992, he focused on central nervous system (CNS) therapeutics, with an emphasis on anticonvulsants and antidepressants. Dr. Maryanoff discovered and championed TOPAMAX® topiramate, a unique sugar sulfamate derivative, which is marketed worldwide for treating epilepsy and migraine headache, and achieved annual sales of more than $2 billion. Since 1991, he has pursued cardiovascular therapeutics, while also seeking drugs for treating pulmonary inflammatory diseases, metabolic disorders and epilepsy. His most recent research has dealt with a wide range of topics. Overall, his drug discovery efforts have led to 23 compounds entering preclinical development, 13 of which advanced into human clinical trials.
Dr. Maryanoff has published 260 scientific papers, is an inventor on 95 US Patents (issued or pending), has presented 160 invited lectures, and has mentored 11 postdoctoral associates.